{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:11:47Z","timestamp":1778562707763,"version":"3.51.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    In the precision management of non-small cell lung cancer (NSCLC), identifying driver mutations and evaluating immune-related biomarkers are essential. Yet, clear therapeutic protocols remain absent for tumors that concurrently carry\n                    <jats:italic>MET<\/jats:italic>\n                    exon 14 skipping mutations (\n                    <jats:italic>MET<\/jats:italic>\n                    ex14) and demonstrate elevated programmed death ligand-1 (PD-L1) expression. This report details the case of a 79-year-old male with a prolonged smoking history who quit 20 years ago, diagnosed with left lung NSCLC. Pathological analysis revealed high PD-L1 expression in the tumor (tumor proportion score 99%), alongside a\n                    <jats:italic>MET<\/jats:italic>\n                    ex14 mutation. Initial therapy employed the PD-1 inhibitor Tislelizumab, yielding a progression-free survival (PFS) of 7 months. Treatment was then modified to the\n                    <jats:italic>MET<\/jats:italic>\n                    tyrosine kinase inhibitor (\n                    <jats:italic>MET<\/jats:italic>\n                    -TKI) Savolitinib, which led to marked tumor reduction. Following discontinuation of Savolitinib due to drug-induced liver injury, Tislelizumab, previously associated with resistance, was reintroduced as a \u201crechallenge\u201d successfully re-establishing disease control. This distinctive therapeutic sequence provides clinical evidence that \u201c\n                    <jats:italic>MET<\/jats:italic>\n                    inhibitors may counteract acquired resistance to PD-1 inhibitors\u201d. Beyond underscoring the value of personalized treatment in the intricate setting of coexisting high PD-L1 expression and\n                    <jats:italic>MET<\/jats:italic>\n                    -driven mutations, this case hints at a novel strategy: sequential\n                    <jats:italic>MET<\/jats:italic>\n                    inhibitor treatment restore sensitivity to immunotherapy responses by modifying the tumor microenvironment. Coupled with a systematic review of pertinent literature, this article explores the clinical features, therapeutic challenges, potential resistance mechanisms, and management approaches for such patients. It also outlines future research avenues for combination or sequential therapies, aiming to furnish a more holistic reference for clinical decision-making.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1807242","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:29:22Z","timestamp":1778560162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and MET exon 14 skipping mutation: a case analysis of overcoming immunotherapy resistance and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yefei","family":"Ruan","sequence":"first","affiliation":[{"name":"The Affiliated Yangming Hospital of Ningbo University, Yuyao People\u2019s Hospital","place":["Yuyao, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Qiu","sequence":"additional","affiliation":[{"name":"The Affiliated Yangming Hospital of Ningbo University, Yuyao People\u2019s Hospital","place":["Yuyao, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pathol.2025.07.009","article-title":"Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series","volume":"58","author":"Li","year":"2026","journal-title":"Pathology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/LCTT.S269307","article-title":"Lung cancer with MET exon 14 skipping mutation: genetic feature, current treatments, and future challenges","volume":"12","author":"Fujino","year":"2021","journal-title":"Lung Cancer Auckl"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1042\/BST20253091","article-title":"Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression","volume":"53","author":"Ghosh","year":"2025","journal-title":"Biochem Soc Trans"},{"key":"B5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.annpat.2015.11.007","article-title":"Pulmonary sarcomatoid carcinoma","volume":"36","author":"Antoine","year":"2016","journal-title":"Ann Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2023.102.19","article-title":"Expert consensus on targeted therapy of NSCLC with MET exon 14 skipping mutation","volume":"26","year":"2023","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010674","article-title":"Determinants of 5-year survival in patients with advanced NSCLC with PD-L1\u226550% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry","volume":"13","author":"Cortellini","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4191","article-title":"Determining the optimal PD\u20101\/PD\u2010L1 inhibitors for the first\u2010line treatment of non\u2010small\u2010cell lung cancer with high\u2010level PD\u2010L1 expression in China","volume":"10","author":"Teng","year":"2021","journal-title":"Cancer Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14448","article-title":"Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations","volume":"13","author":"Uehara","year":"2022","journal-title":"Thorac Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010612","article-title":"Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer","volume":"13","author":"Jeong","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1735","article-title":"First-line MET tyrosine kinase inhibitors versus immunotherapy \u00b1 chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC","volume":"31","author":"Pecci","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00262-025-03984-7","article-title":"Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non\u2013small cell lung cancer","volume":"74","author":"Deng","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1207","article-title":"Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non\u2013small cell lung cancer","volume":"29","author":"Thummalapalli","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32070403","article-title":"MET exon 14 skipping mutations in lung cancer: clinical\u2013pathological characteristics and immune microenvironment","volume":"32","author":"Xue","year":"2025","journal-title":"Curr Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000543251","article-title":"Interstitial lung disease due to tepotinib after durvalumab in a patient with lung adenocarcinoma harbouring MET exon 14 skipping mutation: a case report","volume":"18","author":"Tatsuhige","year":"2025","journal-title":"Case Rep Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.21037\/atm-20-6829","article-title":"Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report","volume":"9","author":"Chen","year":"2021","journal-title":"Ann Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1498391","article-title":"c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity","volume":"15","author":"Jabbarzadeh Kaboli","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.12.004","article-title":"A phase II, open label, single-arm study on the efficacy of cabozantinib in patients with advanced\/metastatic nonsmall cell lung cancer harboring MET exon 14 alterations who developed acquired resistance to tepotinib or capmatinib (CAPTURE trial)","volume":"26","author":"Takeda","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1358\/dot.2021.57.1.3239638","article-title":"Capmatinib for non-small cell lung cancer","volume":"57","author":"Alzofon","year":"2021","journal-title":"Drugs Today Barc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102173","article-title":"Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: a review of preclinical and clinical studies","volume":"95","author":"Wu","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1113696","article-title":"Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: a single-center real-world study","volume":"13","author":"Gow","year":"2023","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194779","article-title":"MET in non-small-cell lung cancer (NSCLC): cross \u2018a long and winding road\u2019 looking for a target","volume":"15","author":"Spitaleri","year":"2023","journal-title":"Cancers Bsl"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1807242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:29:23Z","timestamp":1778560163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1807242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1807242"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1807242","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"article-number":"1807242"}}